John Consigny

"We look forward to building on the strong foundation set by Albert DaCosta and the Paragon 28 team and are excited to officially welcome them to the Zimmer Biomet family," said Ivan Tornos, President and CEO of Zimmer Biomet. "This combination expands our leadership in the foot and ankle segment, one of the highest growth specialties in musculoskeletal care. Together, we will drive innovation at scale and leverage the power of Paragon 28's dedicated foot and ankle commercial channel to help advance our Mission to alleviate pain and improve the quality of life for people around the world."

RS Medical helps healthcare neuromuscular practitioners improve quality of life for patients by providing affordable, COVID-safe, self-managed pain relief and rehabilitation treatments. Since 1990, the company has aided more than 1.5 million patients suffering from painful muscle conditions. Together, we can improve patient outcomes, advance the patient experience and reduce the cost of care.

Leading a high performing team of IDN Managers (#1 Team Rank fiscal 2022-23) to leverage and maximize lifesaving digital (SaaS) resuscitation education solutions to help save more lives from cardiac arrest with strategic IDNs across the U.S. market. Recruited by RQI leadership to scale solutions, build processes, and develop measurable outcomes with new strategic IDN system clients. RQI Partners, LLC, is a partnership between the American Heart Association and Laerdal Medical. We are focused on delivering innovative resuscitation solutions that support our vision to eliminate preventable and unexpected cardiac arrest deaths. We are passionate about, and dedicated to, helping save lives through programs, products, and solutions that are grounded in evidence-based science and educational principles. - Ranked #1 of 7 New Sales IDN Teams; 173% over full fiscal year 2022-23 Net New Subscriptions goal for RQI curricula (33K vs 19K)

Recruited to assist in the development and implementation of a new strategically focused IDN team within the ZOLL Reimbursement organization. Core objectives included identifying, developing, and leveraging value-based coordinated care pilots with targeted IDNs and delegated risk entities such as ACOs, CINs and regional payors. Baseline & comparative cardiac diagnostic data obtained will be utilized to build accretive relationships with partner organizations and bolster market strategies against anticipated new market entrants. - Achieved 100% fiscal Q1 incentive compensation plan payout based on MBO’s inclusive of formal disease state & product training, business planning, and organizational integration. - Secured two validated pilot opportunities with cardiology practices affiliated with Henry Ford Health System and SSM in Q2.

Executive Director of the Year 2020. Our team builds executive level relationships with strategic IDNs, GPOs, and GPO collaboratives to understand and address their needs through the depth and breadth of Integra’s medical device product and solutions portfolio. I lead and collaborate with multiple internal and client teams to create strategic, mutually beneficial, committed contractual partnerships ($43M annual business portfolio). Integra Lifesciences is a global leader in medical devices offering innovative solutions in neurosurgery, reconstructive and general surgery, regenerative wound & burn care, and orthopedic extremity surgery. - Achieved & Recognized for #1 Executive Director of 2020; 112.3% to incentive compensation plan performance in FY 2020 - Achieved 100% to incentive compensation plan performance in FY 2019

Consistent sales revenue plan achiever. Recruited to lead corporate accounts initiatives within strategic IDNs and key GPO shareholder systems in the Midwest. Responsible for maximizing sales and profitability of a $34M annual business portfolio to achieve sales plan objectives impacting 7 business units including Vascular Access, Anesthesia, Respiratory, Surgical, Interventional Access, Cardiac Care, and Urology. - Achieved 104% to incentive compensation sales plan performance in FY 2014 - Achieved 100% to incentive compensation sales plan performance in FY 2015 - Achieved 101% to incentive compensation sales plan performance in FY 2016

Responsible for achieving capital sales plan objectives through 2 districts comprised of 2 District Managers, 13 Account Executives, and 3 Clinical Resource Specialists across 9 Upper Midwest states. Established and executed IDN, key account, and GPO Collaborative strategies to realize increased capital sales revenue and market share for ArjoHuntleigh therapeutic bed frames, specialty therapy systems (Rotoprone, Low Air Loss, Percussion), and therapeutic surfaces within the critical care, bariatric, and wound care market segments. Served as Interim District Sales Manager to lead the Great Lakes Sales District from August 2013 through March 2014 while the current manager had been on extended medical leave. Responsible for leading 9 direct reports to achieve asset rental and capital revenue targets, sales call reach and frequency KPI objectives, training, field coaching, transitioning operational and customer service systems, leading various key account initiatives, and numerous RFP opportunities.

Strategic Accounts Manager ConvaTec Healthcare Solutions Selected by the VP of Corporate Accounts to develop and be a key contributor in a new fee-for-service consulting division, ConvaTec Healthcare Solutions™ (CHS), a key growth strategy for the U.S. executive leadership team. Leveraged electronic charting solutions, proprietary treatment methodologies, and outpatient wound clinic consulting services with senior level client leadership to improve the scale and relevance of ConvaTec value propositions resulting in significant new revenue growth, improved clinical outcomes, and operational efficiencies. - Realized 120.5% YTD business plan performance ($2.1MM annually) vs. U.S. performance of 99% YTD plan.

Led all aspects in managing assigned key IDN accounts and identified emerging opportunities directly impacting the U.S. Central Area revenue goals. Effectively collaborated with the Area Vice President and Region Sales Managers on Central Area strategy development, key account selection, senior level key account interactions, strategic targeting initiatives, custom contracting, and financial analysis to retain, expand, and grow business across 4 business units including Wound Therapeutics, Critical Care, Ostomy, and Negative Pressure Therapy. - Numerous 2009 contracts won and defended inclusive of CAPTIS (formerly Vizient UMCSC purchasing collaborative) and Franciscan Alliance.

Managed and achieved U.S. direct sales attainment for the DuoDERM® Hydrocolloid brand ($26MM Annual Sales) and Foundation product portfolio of compression bandages, wound cleansers, and wound gels ($20MM Annual Sales). Key marketing responsibilities included strategic brand planning, utilization of marketing analytics, new product & market development, strategic pricing, brand promotion, global branding input, KOL development, e-commerce development, national sales meeting leadership, and national symposia management. - Achieved 105% to 2008 plan for DuoDERM® brand and 105% to 2008 plan in Foundation brands ($46MM Total Portfolio). - Kaiser Permanente IDN – Realized $680K of new brand revenue by leading an innovative collaboration with Corporate Accounts and inVentiv Health professional education. Recognized by Global Marketing for best practice success. - Selected to lead the U.S. Wound Therapeutics e-commerce initiative to fully re-tool www.convatec.com content, develop digital marketing vision, and assess new capabilities with vendors and agencies inclusive of Publicis Healthware.

Led and inspired the turnaround performance and activities of 9 Territory Managers to achieve ConvaTec sales and business objectives through the application of situational leadership and core behaviors. Deliverables included attainment of regional sales budget, development and execution of IDN and targeted account strategies, skills development, performance coaching, talent acquisition, and management of operational budget. Responsible for increasing revenue within all ConvaTec product lines (skin care, wound care, fecal management, ostomy) utilized throughout the continuum of care (OR, ICU, PEDS, ONC, IR, ED, PT, Outpatient Clinics, Long Term Care, Home Care, DME). - Consistent over achievement of Region sales plan goals in 2005, 2006, and 2007 - reversing inherited 2004 under performance. - Multiple Club Diamond TM performances attained (Top 10% Performances). - Area of The Year Management Team Member 2005.

Fully responsible for impacting U.S. organizational productivity and profitability by leading the sales training and leadership development programing for the U.S. field sales organization with support to Latin America and Canada. Successfully progressed through leadership/management development track initiatives including RMI “Performance Leadership” programs, Miller Heiman Client Associate certification, Vital Learning Coach certification, Experience Based Interviewing, and other various ConvaTec leadership & sales effectiveness training.

Effectively led the turnaround performance of a previously poor performing territory representing ostomy, patient skin care, and advanced wound care products and solutions to the Central IL acute care, long-term care, home care, and retail markets. Earned and executed additional responsibilities within the region and area encompassing Marketing projects (Hyalofil® limited market release), interviewing, training, distribution partnership initiatives, and various symposia representation. - Consistent over achievement of territory sales performance plan in 2001 and 2002 - reversing significant under performance in 1999.

Successfully represented three product lines including gastrointestinal and oral anti-fungal products by utilizing various sales competencies including objective based business planning, strategic partnering, product knowledge, and selling skills. Market included gastroenterology, dermatology, and podiatry. Selected as District Training Coordinator for the Aciphex® new product launch resulting in accelerated sales. - Aciphex® market share district leader 3.79% (territory) vs. 2.34% (district) #1 of 10 (1999) - Aciphex® market penetration district leader 7.29% (territory) vs. 4.05% (district) #1 of 10 (1999).